Ranbaxy Receives Approval To Market RAN™-Donepezil In Canada

MISSISSAUGA, Ontario, Jan. 7, 2014 /CNW/ - Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RPCI received approval on December 24, 2013 to manufacture and market RAN™-Donepezil Hydrochloride 5 mg and 10 mg tablets from Health Canada. Total market size of Aricept* (Donepezil Hydrochloride) in Canada is $153.9 million ($CAD) [IMS-CDH: November - 2013] and growing at 38% (extended units). Donepezil Hydrochloride is indicated in the treatment of dementia in Alzheimer's patients.

"We are pleased to have gained approval for Donepezil Hydrochloride from Health Canada and proud to announce a day one launch! The finished dosage form will be manufactured at Ohm Laboratories located in New Jersey, U.S.A. and Ranbaxy anticipates this launch will be beneficial to patients and healthcare professionals, as well as a positive economic benefit to the healthcare system of Canada," said Paul Drake, President, RPCI.

Ranbaxy Pharmaceuticals Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.

*Aricept® is a registered trademark of Pfizer Canada Inc.

CONTACTS:

Charles M. Caprariello

Paul Drake


Vice President, Corporate Communications

President


Ranbaxy Inc.

Ranbaxy Pharmaceuticals Canada, Inc.


(609) 720-5615

(905) 219-8820

SOURCE Ranbaxy Pharmaceuticals Canada Inc.

For further information:

http://www.ranbaxy.com